C07K 14/70553
Integrin beta2-subunit-containing molecules
Official title: {Integrin beta2-subunit-containing molecules, e.g. CD11, CD18}
C07K14/70553 (Integrin beta2-subunit-containing molecules) appears on 73 US grants and 63 published applications in this corpus.
Search patents in C07K- Granted patents
- 73
- Published applications
- 63
- Assignees
- 51
- Inventors
- 170
- Latest grant
- 24 Mar 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1994 | 2 | 0 |
| 1995 | 4 | 0 |
| 1996 | 2 | 0 |
| 1997 | 2 | 0 |
| 1998 | 12 | 0 |
| 1999 | 4 | 0 |
| 2000 | 4 | 0 |
| 2001 | 4 | 1 |
| 2002 | 2 | 2 |
| 2003 | 3 | 4 |
| 2004 | 1 | 3 |
| 2005 | 1 | 2 |
| 2006 | 2 | 1 |
| 2007 | 0 | 3 |
| 2008 | 1 | 0 |
| 2009 | 0 | 2 |
| 2010 | 1 | 2 |
| 2011 | 2 | 2 |
| 2012 | 0 | 0 |
| 2013 | 0 | 1 |
| 2014 | 1 | 0 |
| 2015 | 2 | 4 |
| 2016 | 0 | 2 |
| 2017 | 3 | 2 |
| 2018 | 1 | 4 |
| 2019 | 2 | 2 |
| 2020 | 3 | 8 |
| 2021 | 4 | 5 |
| 2022 | 1 | 1 |
| 2023 | 4 | 4 |
| 2024 | 1 | 1 |
| 2025 | 3 | 3 |
| 2026 | 1 | 4 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Quadricistronic system comprising a homing receptor and chimeric antigen receptor for stable genetic modification of cellular immunotherapies24 Mar 2026US 12,584,138 B2ImmunityBio, Inc.
- I domain chimeric antigen receptor specific to ICAM-19 Sep 2025US 12,410,235 B2Cornell University
- Transduced T cells expressing human SSTR2 and application thereof10 Jun 2025US 12,325,736 B2Cornell University
- Reagents and assays using modified integrin domains6 May 2025US 12,291,562 B2149 Bio, LLC
- Mammalian alveolar macrophages derived from pluripotent cells19 Nov 2024US 12,146,161 B2The Hosptial for Sick Children
- Application of CCR5hi Innate Immune Memory Cells in Preparation of Immunotherapeutic Drug for Treating Sepsis8 Oct 2026US 2026/0306538 A1Children's Hospital of Soochow University
- Quadricistronic system comprising a homing receptor and chimeric antigen receptor for stable genetic modification of cellular immunotherapies20 Aug 2026US 2026/0242801 A1ImmunityBio, Inc.
- Integrin beta 2 (cd18) gene-edited bovine cells and animals with reduced susceptibility to mannheimia haemolytica leukotoxin a (lkta)16 Apr 2026US 2026/0103505 A1
- Itgb2-mediated drug delivery system1 Jan 2026US 2026/0000782 A1Twinpig Biolab Inc.
- Genetically engineered cells and uses thereof27 Nov 2025US 2025/0361488 A1
Most cited
By later US patents
- Peptide medicaments for the treatment of disease50US 5,340,800 A1994
- Chimeric receptors for the generation of selectively-activatable TH-independent cytotoxic T cells45US 6,083,751 ATargeted Genetics Corporation · 2000
- Product and process for T lymphocyte immunosuppression41US 6,264,950 B1National Jewish Medical and Research Center · 2001
- Human .beta..sub.2 integrin .alpha. subunit34US 5,470,953 AICOS Corporation · 1995
- Human CR3.alpha./.beta. heterodimers32US 5,424,399 AChildren's Medical Center Corporation · 1995